LogIn PORTAL

Discovering New Innovations in Oncology

Original Air Date:5/31/2022

Duration:60 minutes

Enter your email address to log in to the webinar.

If you are not registered for this webinar, click below to sign up:

Register Now!

Speakers

David Bunka, PhD

Chief Technical Officer

Aptamer Group

David holds a PhD in Molecular Biology and has spent nearly 20 years developing nucleic acid aptamers against a wide variety of targets including small molecules (antibiotics, food contaminants, chemotherapeutics), disease-associated proteins, several cancer-associated cell-lines, viruses and tissue biopsies. This work has been facilitated through the use of high-throughput, automated aptamer selection methods. David has built up an established international reputation in the field and has authored several peer-reviewed research articles, invited review articles and a book chapter on aptamer-based therapeutics. He has also given many guest seminars covering aptamer-based applications at top universities and international conferences.

Cathie Miller, PhD

Senior Director of Product Marketing, Personalized Medicine

BioIVT

After beginning her research career at the University of Michigan, Cathie received her Ph.D. at the University of Louisville School of Medicine before completing her post-doctoral fellowship at the Wistar Institute and the University of Pennsylvania. With a career that spans over 20 years at the bench, as well as a Director and a Global Product Manager, all involving the use of biospecimens in the fields of cancer, immunology and virology, Cathie is now Senior Director of Product Marketing, Personalized Medicine, at BioIVT.

Henry Sebesta

BD

KromaTiD

Henry Sebesta is a dedicated life sciences industry professional with over 5 years of experience in gene therapy product and business development. Through years of market analysis and direct collaboration with thought leaders across the industry, Mr. Sebesta has helped guide the development of KromaTiD's full suite of gene and cell therapy solutions. He is also a contributing author on KromaTiD's 'dGH for Gene Editing' publication currently under review, and co-inventor on KromaTiD's most recent IP for determining genotoxicity and relative risks of cell and gene therapies.

Email Address

Password

Forgot Password?

If you receive an "Already Logged In" message, wait 1 minute before re-entering.


Terms Of Use | Privacy Policy | Computer Tips | Login Help

By logging in, you agree to the Terms of Use and Privacy Policy.

By participating in this webinar, you acknowledge that the data collected herein will be processed by InsideScientific in accordance with the Privacy Policies linked below.

InsideScientific Privacy Policy | Intrado Privacy Policy | System Check  | Technical RequirementsTerms of Use  | Contact Us